StimCell Enegetics

StimCell Enegetics Current Assets

The Current Assets of StimCell Enegetics (STME) as of Oct 30, 2026 is 3,028.00 USD. In the previous year, Current Assets was 21,222.00 USD — a change of -85.73% (lower).

Current Assets

3,028.00USD

YoY

-85.73%

Last updated:

Current Assets of StimCell Enegetics is 2026 3,028.00 USD. Current Assets of StimCell Enegetics was 2025 21,222.00 USD. It decreases by -85.73% lower compared to the previous year.

The StimCell Enegetics Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
180,704.00 USD
Jan 1, 2020
140,997.00 USD
Jan 1, 2021
38,624.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
91,270.00 USD
Jan 1, 2024
44,315.00 USD
Jan 1, 2025
21,222.00 USD
Jan 1, 2026
3,028.00 USD
The StimCell Enegetics Current Assets history
YEARCurrent AssetsYoY
3,028.00USD-85.73%
21,222.00USD-52.11%
44,315.00USD-51.45%
91,270.00USD—
0.00USD-100.00%
38,624.00USD-72.61%
140,997.00USD-21.97%
180,704.00USD+161.23%
69,174.00USD-30.93%
100,157.00USD+61.95%
61,844.00USD+198.50%
20,718.00USD+1,625.06%
1,201.00USD-89.06%
10,979.00USD-53.51%
23,615.00USD+138,811.76%
17.00USD-99.91%
20,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StimCell Enegetics Stock analysis

What does StimCell Enegetics do? Cell MedX Corp. makes money through its subsidiary Avyonce Cosmedics Inc., which resells spa technology and equipment to the beauty and wellness industry. Avyonce also markets eBalance Technology, used for micro current treatments targeting diabetes and related ailments, and conducts observational studies with this technology. The company provides continuing education for estheticians and healthcare professionals in medical aesthetics. Avyonce Cosmedics Inc. serves the beauty and wellness industry, focusing on professionals who use spa technology and equipment. The firm develops a family of devices based on eBalance Technology, which is applied in treatments for diabetes and related conditions. This technology is central to Avyonce's product offerings and educational services. Cell MedX Corp. operates as a development stage company with no full-time employees, relying on its subsidiary Avyonce to drive revenue. The company's business model centers on the commercialization of eBalance Technology through product sales, educational programs, and observational studies in the medical aesthetics sector. StimCell Enegetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StimCell Enegetics stock

Current Assets of StimCell Enegetics is 3,028.00 USD in 2026.

Current Assets of StimCell Enegetics changed from 21,222.00 USD to 3,028.00 USD, representing a -85.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets StimCell Enegetics since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's StimCell Enegetics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — StimCell Enegetics

All Key Metrics — StimCell Enegetics